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ABSTRACT Influenza viruses are characterized by a high degree of antigenic variability, which causes the annual emer-
gence of flu epidemics and irregularly timed pandemics caused by viruses with new antigenic and biological traits. 
Novel approaches to vaccination can help circumvent this problem. One of these new methods incorporates genetic 
vaccines based on adenoviral vectors. Recombinant adenoviral vectors which contain hemagglutinin-encoding genes 
from avian H5N1 and H5N2 (Ad-HA5-1 and Ad-HA5-2) influenza viruses were obtained using the AdEasy Adenoviral 
Vector System (Stratagene). Laboratory mice received a double intranasal vaccination with Ad-HA5-1 and Ad-HA5-2. 
This study demonstrates that immunization with recombinant adenoviruses bearing the Н5 influenza virus hemag-
glutinin gene induces a immune response which protects immunized mice from a lethal dose of the H5 influenza virus. 
Moreover, it also protects the host from a lethal dose of the H1 virus, which belongs to the same clade as H5, but does 
not confer protection from the subtype H3 influenza virus, which belongs to a different clade. 
Our data allow us to conclude that adenoviral vectors may become a universal platform for obtaining vaccines against 
seasonal and pandemic strains of the influenza virus.
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INTRODUCTION 
Influenza A viruses can cause severe epidemics. These viruses 
are widespread in nature and can infect humans, many mam-
malian species (horses, pigs, seals, etc.), and all species of birds 
[6, 17]. Different strains of the influenza virus are traditionally 
named after the numerical indexes of their surface antigens 
(hemagglutinin (HA) and neuraminidase (NA)). Overall, there 
are 15 subtypes of hemagglutinin and 9 subtypes of neuramin-
idase with minimal cross-activity in serological reactions be-
tween subtypes [18]. Two subtypes of hemagglutinin (Н1, Н3) 
and two types of neuraminidase (N1–N2) are currently cir-
culating in the human population [18, 20]. Another potential 
threat to humans comes from avian influenza viruses, which 
have H5 hemagglutinin, since numerous cases of humans being 
infected by the H5N1 have been reported as far back as 1997. 
This virus was first detected in a human organism in China 
more than 10 years ago [7]; according to the WHO, the overall 
number of humans infected with H5N1 is 478, and 286 of such 
cases resulted in death. Influenza A viruses are characterized 
by a very high degree of antigen variability. The most variable 
entities are the surface glycoproteins of the viral particle (he-
magglutinin and neuraminidase). Two mechanisms of variation 
are known. The first is antigenic drift. When a viral population 
is under pressure from the immune system, mutations that al-
low the virus to escape this controlling influence give the virus 
a serious advantage, and thus these mutations are conserved. 
This means that new antigenic variants of hemagglutinin and 
neuraminidase are constantly replacing each other. This cre-
ates the basis for epidemics, since immunity against the previ-
ous virus strain, even if it still belongs to the same subtype, is 
not sufficient to neutralize the new strain. Unfortunately the 
use of modern subunit and inactivated vaccines does not solve 
the problem, since they confer protection only from the strain 
which was used to obtain the vaccine. For this reason new vac-
cines for the protection of the population need to be created 
constantly. 112 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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The second mechanism of influenza virus variation is the 
antigenic shift, which is the alteration of the antigenic formu-
la of a virus via the exchange of a gene (genes) and the cor-
responding protein (proteins). Antigenic shift is based on the 
reassortment or recombination of genes, which can take place 
if an organism is infected by two or more virus strains [19]. 
Shifts most often affect the antigenic structure of hemagglu-
tinin, shifts in neuraminidase being less common. Thus, pan-
demic variants of the influenza virus with new antigenic and 
biological traits can emerge at irregular time periods, causing 
severe diseases and the death of a large number of people 
[6, 17]. For instance, the pandemic of the so-called “Spanish 
flu” – an H1N1 influenza virus in 1918–1920 – caused the 
death of around 50 million people worldwide. In June 2009, 
the World Health Organization (WHO) called the new H1N1 
virus, cases of which started cropping up in April 2009, a 
6th degree pandemic threat. This virus was the result of a 
reassortment, which combined the genes of avian, human, 
and porcine viruses [8]. If a new pandemic virus emerges, 
the creation of a vaccine takes too long, thus preventing a 
swift end to the spread of the dangerous virus. Circumvent-
ing this problem requires the creation of novel approaches 
to vaccinations against influenza viruses. One such approach 
is the creation of genetic vaccines based on viral vectors [5, 
11]. The most promising type of genetic vaccines is a vac-
cine based on adenoviral vectors [1, 2]. Until recently it was 
thought that influenza-targeted vaccines, including genetic 
varieties which used variable surface antigens of influenza 
viruses (hemagglutinin and/or neuraminidase), were strictly 
specific to the strain whose antigen was used during the cre-
ation of the vaccine. However, studies performed in recent 
years (2008–2009) demonstrate that genetic vaccines based 
on adenoviruses which contain the hemagglutinin gene from 
an A-type influenza virus can induce cross-immunity both 
inside a single subtype of influenza virus [3] and between 
different subtypes of a virus that share the same subtype of 
hemagglutinin [15]. Such an effect may be caused by the fact 
that an organism vaccinated by an adenovirus receives an 
influenza virus hemagglutinin gene, which is then effectively 
expressed in the cell and is exposed on the plasma membrane, 
retaining its native ternary structure. This induces both cel-
lular and humoral responses to the conservative epitopes of 
the influenza virus hemagglutinin. It was demonstrated that 
antibodies obtained from human plasma cells infected by an 
H5N1 influenza virus could also neutralize H1-subtype virus-
es as well [4]. Data published in 2008 also show that influenza 
viruses can be divided into two groups according to the pres-
ence of highly conservative conformational epitopes in the 
hemagglutinin molecule which can be identified by broad-
range antibodies. The first group includes subtypes H1, H2, 
H5, H6, H8, H9, H11, H12, H13, and H16; the second includes 
subtypes H3, H4, H7, H10, H14 and H15. Antibodies against 
the antigenic determinants of the first group are not equally 
effective for the neutralization of viruses of this group, but 
they do not neutralize viruses from the second group [14]. 
These groups were divided into four subgroups or clades ac-
cording to the presence of conservative epitopes: Н1 clade 
(H1, H2, H5, H6, H11, H13 and H16 hemagglutinins), Н9 clade 
(H9, Н8 and Н12), Н7 clade (Н15, Н7 and Н10) and Н3 clade 
(Н3, Н14 and Н4).
Thus we have proposed that vaccination by an adenoviral 
vector bearing the the hemagglutinin gene of an Influenza 
A virus can lead to the production of antibodies against con-
servative epitopes (some of which may be conformational) 
of the major Influenza A surface antigen. This provides a 
cross-subtype immune response not only against influenza 
A viruses from a single subtype, but also against viruses of 
various subtypes which belong to the same clade. 
This study used recombinant human adenoviruses of the 
fifth serotype which bore hemagglutinin genes from the avi-
an influenza viruses H5N2 and H5N1, since the Н5 subtype 
avian viruses are likely candidates for the next pandemic 
strain. It was shown that immunization with recombinant 
adenoviruses induced the induction of a protective immune 
response, which allowed mice to survive lethal doses of its 
“native” H5 strain, and protected against a lethal dose of H1, 
which belongs to the same clade as H5. However this immune 
response did not protect the mice from an H3-subtype virus 
belonging to a different clade.
EXPERIMENTAL PROCEDURES
Viruses. This study used an avian influenza virus A/Mal-
lard/Pennsylvania/10218/84 (H5N2) and human influenza 
viruses A/USSR/90/77 (H1N1) and A/Aichi/2/68 (H3N2) 
adapted for use on mice [9]. The viruses were accumulat-
ed in the alantoic fluid of chicken embryos at 37°С for 48 
hours. The virus-containing alantoic fluid was stored at 
–70°С. The titer of the virus was calculated by titration in 
chicken embryos. The 50% lethal dosage (LD50) was calcu-
lated by titration on mice. 
Obtaining recombinant adenoviruses. Plasmids and 
recombinant adenoviruses were obtained by using he-
magglutinin genes from an avian influenza A/Mallard/
Pennsylvania/10218/84 (H5N2) virus and a A/Duck/No-
vosibirsk/56/2005 (H5N1) (Н5-2 and Н5-1, respectively). 
The cDNA of the viral genome of A/Mallard/Pennsylva-
nia/10218/84 (H5N2) was obtained by reverse transcription 
using a Reverse Tpanscription System (Invitrogene, United 
States). The hemagglutinin НA5-2 was obtained by amplify-
ing the cDNA with primers which flanked the hemagglutinin 
gene. The Н5-1 hemagglutinin gene was supplied by the Viral 
Disease diagnostic laboratory of the All-Russian Research 
Institute of Animal Health (Vladimir).
Recombinant adenoviruses Ad-HA5-1 and Ad-HA5-2 
were obtained by homologous recombination in E.coli cells 
using the AdEasy Adenoviral Vector System (Stratagene). 
The obtained adenoviruses were purified and concentrated 
by double ultracentrifugation in a cesium chloride gradient. 
A recombinant serotype 5 human adenovirus with no expres-
sion cassette in the region of deletion in the E1 area of the 
genome was used as a control (Ad-null). The titers of the Ad-
HА5-1, Ad-HА5-2 and Ad-null preparations were calculated 
using plaque formation in a HEK-293 cell culture. 
Detection of hemagglutinin gene expression by IFA. He-
magglutinin gene expression by the recombinant viruses was 
performed on HEK-293 cells inoculated with the Ad-HА5-1 
and Ad-HА5-2 vectors at a dosage of 100 particles per cell. 
After 24 h of incubation, the cells were lysed and ELISA was 
performed using a kit for the detection of H5 avian influenza 
strain hemagglutinin (BioAssay).RESEARCH ARTICLES
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Measuring levels of hemagglutinin-binding antibodies in 
murine serums. Antibody levels in murine serums were as-
sayed 21 days after the second immunization. The hemagglu-
tinin-binding antibody level in murine serums was assayed by 
a hemagglutination-inhibition reaction performed according 
to the WHO/CDS/CR S/NC S/2002.5 protocol using chicken 
erythrocytes. 
Mice. The mice used in this study were females of the 
BALB/c line and weighed about 7–9 g.
Animal immunization. The mice were divided into groups 
(ten animals per group) and immunized twice by an intrana-
sal dose of recombinant Ad-HА5-1 and Ad-HА5-2 viruses, 
108 PFU/mouse. The interval between immunizations was 21 
days. The control groups were immunized with the Ad-null 
virus or treated with PBS solution instead.
Animal infection. Twenty-one days after the second im-
munization, the mice were lightly anaesthetized with ether 
and then received a lethal dose (50 LD50) of the A/Mallard/
Pennsylvania/ 10218/84 (H5N2) strain or lethal doses (10 
LD50) of A/USSR/90/77 (H1N1) and A/Aichi/2/68 (H3N2) 
strains. The survival and changes in mouse weight were 
measured for 16 days after infection. 
RESULTS AND DISCUSSION
Detection of hemaglutinnin gene expression in recombinant 
Ad-HА5-1 and Ad-HА5-2 adenoviruses. Schematics of the 
genomes of the recombinant Ad-НА5-1 and Ad-HA5-2 aden-
oviruses, which were obtained by homologous recombination 
in E.coli cells, are presented in Fig. 1А. The obtained prepara-
tions of adenoviral vectors were assayed for the presence of 
avian H5N1 and H5N2 influenza hemagglutinin gene inser-
tions in the genomic DNA by PCR (data not shown).
Lysates obtained from HEK-293 cells infected with the re-
combinant Ad-HA5-2 adenovirus were assayed for the expres-
sion of recombinant hemagglutinin by ELISA using a kit for the 
detection of avian H5 influenza hemagglutinin (Fig. 1B). The 
expression of avian H5N1 influenza hemagglutinin by the Ad-
HA5-1 adenovirus was assayed similarly (data not shown).
Assay for the immunogenicity of Ad-HA5-2-expressed 
hemagglutinin and the cross-immunogenicity of Ad-HA5-
1-expressed hemagglutinin. The level of antibodies secreted 
against the recombinant hemagglutinin produced by the Ad-
HA5-2 adenovirus was assayed using a hemagglutination-
inhibition reaction. Mice of the BALB/c line were immunized 
with the Ad-HA5-2 adenovirus. Mice injected with PBS 
buffer were used as controls. Mice sera obtained 21 days af-
ter repeated immunization were analyzed for the presence of 
specific antibodies against avian influenza strain A/Mallard/
Pennsylvania/10218/84 (H5N2). The hemagglutination-inhi-
bition reaction results are presented in Fig. 2. The sera from 
mice immunized with the recombinant Ad-HA5-2 adenovirus 
appeared to have high levels of antibodies, which inhibited 
the agglutination of erythrocytes by the H5N2 virus. These 
data indicate the induction of a humoral immune response 
specific to the H5N2 avian influenza virus following the in-
tranasal injection of a recombinant adenovirus expressing the 
H5 hemagglutinin gene.
The cross-immunogenicity of Ad-HA5-1-expressed he-
magglutinin was assayed in a similar manner. The sera ob-
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Fig. 1. The recombinant human adenovirus of the 5th serotype expresses 
the hemagglutinin gene of the avian H5N2 influenza virus (A/Mallard/
Pensylvania/10218/84) in infected cells. (А) A schematic of the genome 
of the recombinant adenovirus, which bears the influenza virus hemag-
glutinin. (B) Expression of the H5N2 virus hemagglutinin by line 293 human 
embryo kidney cells infected with Ad-HА5-2 (ELISA): (-) negative control, 
(-) positive control,  (-) lysates prepared from cells untransfected by Ad-
HA5-2, and (-) lysates prepared from cells transfected by Ad-HA5-2
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Fig. 2. Level of specific hemagglutinating antibodies which neutralize the 
avian H5N2 influenza virus in sera obtained from mice immunized by the 
recombinant Ad-HA5-1 and Ad-HA5-2 adenoviruses. Mice were im-
munized with Ad-HA5-1 and Ad-HA5-2 adenoviruses twice. Mice immu-
nized by either Ad-null or PBS solution were used as controls. Antibody 
titers in mouse sera were assayed by HRR against the influenza A/Mal-
lard/Pensylvania/10218/84 (H5N2) virus. A significant difference was 
detected between the control groups immunized with Ad-null and PBS 
and the groups vaccinated with Ad-HA5-1 and Ad-HA5-2 (p < 0.05)114 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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tained after immunization were assayed for the presence of 
specific antibodies against avian influenza A/Mallard/Penn-
sylvania/10218/84 (H5N2) hemagglutinin using hemaggluti-
nation-inhibition reaction (Fig. 2.). The tested mice sera had 
high levels of antibodies that prevented the agglutination of 
erythrocytes by the H5N2 influenza virus.
These results indicated the induction of a heterosubtypic 
humoral immune response specific to the H5N2 avian influ-
enza virus following the immunization of mice by adenovi-
ruses expressing the hemagglutinin gene from the H5N1 
avian influenza virus. The amount of antibodies specific to 
the H5N1 viral hemagglutinin was lower than in the case of 
immunization by an adenoviral vector bearing the H5N2 in-
fluenza hemagglutinin, but was still relatively high compared 
to the control group. 
In control (PBS) sera, some nonspecific hemagglutination 
inhibition was observed due to the components of the murine 
serum. 
Protective immunity of mice immunized by Ad-HA5-2 
and cross-immunity of Ad-HA5-1-infected mice against 
H5N2 avian influenza virus infection. In order to study the 
protective effect of a double immunization with Ad-HA5-2, 
the immunized animals were infected with a lethal dose (50 
LD50) of the A/Mallard/Pennsylvania/10218/84 (H5N2) in-
fluenza virus. The control mice were injected with the Ad-
null recombinant adenovirus and with PBS solution. Mice 
which were immunized with the AdHA5-2 adenovirus did 
not lose any weight after infection and had 100% survival. 
The control PBS group, on the other hand, showed a 100% 
mortality rate over the course of 10 days and a 20% reduc-
tion in weight. The Ad-null group showed 20% survival and 
30% weight reduction (Fig. 3). Thus, immunization with the 
recombinant Ad-HА5-2 adenovirus protected mice from a 
lethal H5N2 influenza virus infection. In order to study the 
induction of protective cross-immunity, mice were immu-
nized as was described above by a recombinant Ad-HА5-1 
adenovirus and infected with a lethal dose (50 LD50) of the 
A/Mallard/Pennsylvania/10218/84 (H5N2) virus. The im-
munization of mice with the Ad-HА5-1 adenovirus induced 
a heterosubtypic cross-immune response against the H5N2 
influenza virus. The immunized mice showed no reduction in 
weight and had a 100% survival score (Fig. 3). 
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Fig. 3. Analysis of the protective hemagglutinin-specific immune response in mice immunized by recombinant Ad-HA5-1 and Ad-HA5-2 adenovi-
ruses and later infected by a lethal dose of avian influenza virus H5N2. (А) Survival of mice infected by a lethal dose (50LD50) of the A/Mallard/
Pensylvania/10218/84H5N2 (H5N2)-strain virus. Mice were immunized twice with the Ad-HA5-1 and Ad-HA5-2 adenoviruses. Control mice were 
immunized twice either with Ad-null or with PBC solution. The differences in survival between the Ad-HA5-2 (Ad-HA5-1) groups and the PBS control 
group (р < 0.00001) and the Ad-null control group (p < 0.0001) were statistically significant. (B) Changes in mouse weight as measured for the mice 
treated with 50LD50 of the A/Mallard/Pensylvania/10218/84H5N2 (H5N2) virus.
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Fig. 4. The level of specific hemagglutinating antibodies against H1N1 
and H3N2 viruses in the sera of mice immunized with the recombinant 
Ad-HA5-2 adenovirus. The mice were immunized with the Ad-HA5-2 
adenovirus twice. Control mice were immunized with PBS solution twice. 
The antibody titer in mice sera was assayed using HRR against A/
USSR/90/77 (H1N1) and A/Aichi/2/68 (H3N2) viruses. The difference 
between the vaccinated and control groups as assayed by HRR against 
the H1N1 was statistically significant (p = 0.05), while the HRR against 
the H3N2 virus showed no significant difference (p > 0.05)RESEARCH ARTICLES
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Assaying the cross-immunogenicity of Ad-HA5-2-ex-
pressed hemagglutinin against H1N1 and H3N2 viruses. 
The cross-immunogenicity of recombinant hemagglutinin 
expressed by the Ad-HA5-2 adenovirus was assayed by the 
hemagglutination-inhibition reaction. BALB/c mice were 
immunized by the Ad-HA5-2 adenovirus as previously de-
scribed. Control mice were intranasally injected with PBS 
solution. Samples of mice serum were collected 21 days after 
the second immunization. These samples were assayed for the 
presence of antibodies specific to A/USSR/90/77
(H1N1) and A/Aichi/2/68 (H3N2) influenza hemaggluti-
nin (results show on Fig. 4). Sera from mice immunized with 
the recombinant Ad-HA5-2 adenovirus were found to ex-
hibit a pronounced increase of anti-H1N1 antibody titers in a 
hemagglutination-inhibition reaction assay when compared 
to the control group. There was no statistically significant dif-
ference in the hemagglutination inhibition levels between the 
anti-H3N2 reaction in sera from the Ad-HA5-2-immunized 
mice and the nonspecific inhibition due to components of the 
control murine serum.
The obtained result indicated the induction of a humoral 
immune response specific to the H1N1 influenza virus in re-
sponse to immunization by a recombinant Ad-HA5-2 adeno-
virus. The efficacy of the humoral immune response against 
the H3N2 influenza virus proved to be insignificant.
Assaying the cross-protection of mice immunized with 
Ad-HA5-2 against the influenza A viruses H1N1 and H3N2. 
After the second Ad-HA5-2 immunization, mice were inject-
ed with lethal doses (10 LD50) of A/USSR/90/77 (H1N1) and 
A/Aichi/2/68 (H3N2) viruses. Control mice were intranasally 
injected with PBS solution. This experiment showed that im-
munizing animals with the recombinant Ad-HA5-2 adenovi-
rus protected mice from a lethal dose of the H1N1 influenza 
virus. Mice did not die during the whole observation period, 
and their weight reduction was approximately 5%. The con-
trol group injected with PBS showed 100% mortality over 9 
days and a weight reduction of 30%. Immunizing mice with 
the Ad-HA5-2 adenovirus did not protect mice from a lethal 
dose of the H3N2 influenza virus. The immunized mice exhib-
ited 20% survival and almost 40% weight reduction (Fig. 5).
Discussion. Protecting the human population from the 
constant threat of influenza is problematic due to the dif-
ficulty of predicting the appearance of new pandemic and 
epidemic strains, as well as to the low cross-reactivity of inac-
tivated and subunit vaccines, which are effective only against 
the strain of virus they were manufactured from. Vaccines 
which would provide a broad range of protection from po-
tentially dangerous influenza virus strains are still a goal that 
is hard to achieve. 
It is known that influenza infection can confer heterosub-
typic immunity based on both the humoral and cellular im-
mune responses. A heterosubtypic immune response can con-
siderably decrease the duration of the disease and reduce the 
symptoms of infection by a different viral strain [21]. The in-
duction of a heterosubtypic immune response occurs, among 
other things, due to the presence of conformational epitopes 
in hemagglutinin, which are conserved in various strains of 
the influenza virus. 
The existence of a conformational epitope shared between 
several subtypes has been demonstrated for influenza A he-
magglutinin [10]. In recent studies, various subtypes of the 
influenza virus have been divided into groups (clades) accord-
ing to the presence of conservative hemagglutinin epitopes, 
which are recognized by antibodies that thus are able to neu-
tralize a wide range of viral subtypes. This can be explained 
by the genetic relations between hemagglutinins from differ-
ent viral subtypes. Figure 6 shows a phylogenetic tree of the 
amino acid sequences of influenza virus A hemagglutinins for 
various subtypes. The Н1, H2, and H5 subtypes are all related 
and thus have common conformational epitopes, while Н9, 
H7, and H3 virus subtypes have a low degree of homology 
and thus do not exhibit cross-immunity among themselves. 
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Fig. 5. Analysis of the protective hemagglutinin-specific response in mice immunized by the recombinant Ad-HA5-2 adenovirus and later infected by 
a lethal dose of either the H1N1 or H3N2 virus. (А) Survival of mice infected with a lethal dose (10LD50) of A/USSR/90/77 (H1N1) or A/Aichi/2/68 
(H3N2) influenza virus. Mice were immunized with the Ad-HA5-2 twice in concentration 108 PFU/mouse. Control mice were injected with PBS solu-
tion twice. The differences in survival between the Ad-HA5-2 group (infected with H1N1) and the PBS control group were statistically significant, while 
the differences between the survival in the Ad-HA5-2 group (infected with H3N2) and the PBS control group were not (p = 0.5). (B) Changes in the 
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Since the first clade includes potentially pandemic viral sub-
types (Н5, Н1, and Н2), this makes broad-specificity vaccines 
against this clade especially valuable [12]. Thus, vaccines that 
preserve the stable ternary structure of surface antigens 
should provide effective protection against various influen-
za virus strains. The preparation of subunit and inactivated 
vaccines can often disrupt the structure of viral antigens. 
The use of live influenza vaccines does yield antibodies with 
a broad specificity, but this method has its own significant 
drawbacks. 
Immunization by recombinant adenoviral vectors which 
bear the surface protein genes of the influenza virus leads 
to the expression of influenza virus antigens on the surface 
of the cell without disrupting their ternary structure, which 
in turn makes the induction of a heterosubtypic immune 
response, including the production of broad-specificity an-
tibodies recognizing conservative hemagglutinin epitopes, 
possible. This study used adenoviral vectors with deleted Е1 
and Е3 genomic regions, which allowed us to obtain repli-
cation-defective adenoviral particles and gave the potential 
possibility to use them as vaccine vectors. The advantages of 
using recombinant adenoviruses are the high level of trans-
gene expression in a wide range of eukaryotic host cells, the 
induction of both humoral and cellular responses to the trans-
gene, and their safety for humans (as tested on volunteers) 
[16]. The first phase of clinical trials for a nasal vaccine, based 
on a recombinant replication-defective human adenovirus of 
the fifth serotype bearing a hemaglutinin gene from the H5 
influenza virus, was successfully performed in 2008 in the 
United States [13]. 
Our study used hemagglutinin genes from the avian influ-
enza viruses H5N1 and H5N2, since avian influenza viruses, 
H5N1 especially, are a cause of increasing anxiety. This virus 
is characterized by a mortality rate in excess of 50%, and, if 
it were to acquire the ability to spread from human to hu-
man, it would lead to a pandemic and cause a lot of casualties 
throughout the world. We have constructed adenoviral vec-
tors Ad-HA5-1 and Ad-HA5-2 based on a serotype 5 human 
adenovirus, which contain hemagglutinin genes from viral 
strains A/Duck/Novosibirsk/56/2005 (H5N1) and A/Mal-
lard/Pennsylvania/10218/84 (H5N2). An analysis of the ami-
no acid sequence of these hemaglutinins shows a homology of 
94.6% (http://align.genome.jp/). An analysis of the immuno-
genicity of the obtained Ad-HA5-2 adenovirus showed that a 
double instranasal injection of a recombinant virus expressing 
the H5N2 viral hemagglutinin gene induced the production of 
high titers of antibodies specific towards the avian influenza 
virus A/Mallard/Pennsylvania/10218/84 (H5N2).
We have also demonstrated that a double injection of the 
Ad-HA5-1 virus expressing the H5N1 viral hemagglutinin 
gene induced the production of high titers or cross-reactive 
antibodies against the avian influenza virus A/Mallard/
Pennsylvania/10218/84 (H5N2).
Immunizing mice with Ad-HA5-2 and Ad-HA5-1 adenovi-
ruses protected the animals from a highly lethal dose (50 LD50) 
of the A/Mallard/Pennsylvania/10218/84 (H5N2) influenza 
virus. A control immunization of mice by the Ad-null vector, 
which did not carry any gene expression cassette, allowed 
us to establish the role of the vector itself in the protection 
against influenza A viruses. It turned out that Ad-null im-
munization protected 20% of the animals from the influenza 
virus. This seems to be caused by the induction of a nonspe-
cific antiviral immune response initiated by the injection of 
an adenoviral vector in the animal organism. Thus, we have 
demonstrated that recombinant adenoviruses, which bear 
the influenza virus H5N2 hemaggliutinin gene, can induce 
geterosubtypic immunity between H5N1 and H5N2 influenza 
virus subtypes. 
In order to verify the hypothesis that recombinant ad-
enoviruses can induce broad-specificity antibodies that can 
neutralize viruses of different subtypes belonging to the H1 
clade (H1, H2, H5, H6, H11, H13 and H16), we used the A/
USSR/90/77 (H1N1) virus, which belonged to this clade, and 
A/Aichi/2/68 (H3N2), which did not. According to a study 
A/Kentucky/UR07-0061/2008 H1N1
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A/California/07/2009 H1N1
A/USSR/90/1977 H1N1 A/Puerto Rico/8/1934 H1N1
A/Duck/Korea/CJ54/2004 H5N2
A/Mallard/Pensylvania/10218/84 H5N2
A/Duck/Novosibirsk/56/2005 H5N1
A/Chicken/Egypt/0987-NL QP/2009 H5N1
A/Turkey/England/N28/1973 H5N2
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Fig. 6. A phylogenetic 
tree of the amino acid 
sequences of hemaggluti-
nins of influenza A viruses 
of various subtypes. The 
various subtypes are 
divided into four clades 
based on their degree of 
phylogenetic related-
ness. The strains used in 
this study (highlighted by 
color) belong to clades 
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by M. Throsby and his colleagues [14], H5 and H1 virus he-
magglutinins have a common conservative epitope which is 
formed by the amino acid residues His38, Gln40, and Thr318 
in the HA1 subunit of hemagglutinin and Ile45, Ile48, Thr49, 
and Val52 in the НА2 subunit. The hemaglutinins from Н3 
viruses have Asn and Thr in the 38th and 40th positions in 
the HA1 subunit, as opposed to His and Gln, and Thr and Val 
in positions 49 and 52 instead of Asn and Leu, respectively. 
An analysis of the amino acid sequences of influenza virus 
hemagglutinins in strains A/USSR/90/77 (H1N1), A/
Mallard/Pennsylvania/10218/84 (H5N2), A/duck/Nov-
osibirsk/56/2005 (H5N1), and A/Aichi/2/68 (H3N2), which 
were all used in this study, showed that the described he-
magglutinin epitopes are highly homologues in subtypes H1 
and H5. Only the strain A/duck/Novosibirsk/56/2005 (H5N1) 
has a single substitution (the Gln in position 40 is substituted 
for Val) (Fig. 7). This epitope is, however, significantly differ-
ent in strain A/Aichi/2/68 (H3N2), which does not belong to 
the first clade of influenza viruses. It was shown that double 
Fig. 7. Conserved conformational epitopes of hemagglutinins recognized by neutralizing antibodies specific to the influenza strains used in this work 
and belonging to clades Н1 and Н3. The surface of the hemagglutinin trimer is depicted in the middle; the HA1 chains are depicted in red, green 
and grey; and the HA2 chains are shown in dark blue, light blue and yellow. The region which contains the epitopes for the neutralizing antibodies is 
marked by a black box. The epitopes and the key amino acids that form them are depicted in HA1 (red) and HA2 (blue) hemagglutinin chains of vari-
ous influenza viruses: A/Aichi/2/68(H3N2) (1EO8), A/USSR/90/77(H1N1) (1RVX), A/Mallard/Pensylvania/10218/84H5N2(H5N2) (1JSM) and 
A/Duck/Novosibirsk/56/2005(H5N1) (2IBX)
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TrpB21
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A/Aichi/2/1968 (H3N2)
intranasal immunization with Ad-HA5-2 induced the produc-
tion of antibodies specific to the A/USSR/90/77 (H1N1) virus 
strain. The titer of antibodies that inhibited the agglutination 
of erythrocytes by the H1N1 virus in sera extracted from im-
munized mice was significantly higher than that in the con-
trol group sera. On the other hand, the antibody titers against 
the A/Aichi/2/68 (H3N2) virus as assayed by hemagglutina-
tion-inhibition reaction in immunized mice were statistically 
insignificant when compared with the control for nonspecific 
inhibition by serum components.
In order to assay the protective characteristics of the re-
combinant Ad-HA5-2 adenovirus against lethal doses (10 LD50) 
of A/USSR/90/77 (H1N1) and A/Aichi/2/68(H3N2) viruses, 
we performed a double intranasal immunization of mice. We 
demonstrated that immunization by a recombinant adenovi-
rus conferred 100% protection against a 10 LD50 dose of the 
influenza virus A/USSR/90/77 (H1N1) and, on the other hand, 
protected only 20% of the mice from a 10 LD50 dose of the A/
Aichi/2/68 (H3N2) virus, which probably indicates that this 118 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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moderate protection was due to the nonspecific antiviral im-
mune response induced by the injection of an adenoviral vec-
tor. 
CONCLUSIONS
This study is the first to demonstrate that the introduction of 
an influenza virus hemagglutinin gene via an adenoviral vec-
tor into animal cells induces a protective heterosubtypic cross-
immune response not only against the viruses of the same 
subtype as used for the immunization, but also against viruses 
from various subtypes which belong to the same clade.
These data allow us to conclude that adenoviral vectors can 
work as a universal basis for the production of vaccines against 
both seasonal and pandemic influenza virus strains. 
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